MannKind Corp. (MNKD)

[Denise Chanterelle]

Aloha Crew: Sanofi is not going anywhere.

At a June 10th Healthcare Conference sponsored by Goldman Sachs, the Wall Street powerhouse's analyst, who has a "sell" rating on MNKD, publicly asked the company's executives about Sanofi's options for terminating its Afrezza agreement with MannKind.

It was an odd question on so many levels, not least of all coming so soon after the marketing partner had highlighted the product at the early-June American Diabetes Association convention in Boston.

The provocative question is also noteworthy in that the answer is available in black and white in multiple MannKind filings with the Securities and Exchange Commission, which the analyst would presumably have reviewed; the agreement is spelled out in considerable detail, including conditions that could lead to breakup of the partnership. In any case, the question dovetailed well with the bears' argument, both before and since, that Sanofi may decide to abandon Afrezza due to poor sales.

The bears arguments are weak and w/o any substance. Hold onto your shares my fellow-investors and don't let the detractors pull you down. You will be rewarded handsomely for your patience.